The FDA is poised to approve a “mix-and-match” strategy for COVID-19 booster injections, according to The New York Times.
Americans will be able to obtain a different brand booster than what they were previously provided thanks to the permission.
The FDA Intends To Allow Patients To Mix & Match Vaccine
According to The Times, it will not advocate one brand over another, although it may remark that obtaining the same brand is desirable.
The Food and Drug Administration is likely to authorize a “mix-and-match” strategy for Americans seeking booster injections, according to The New York Times, allowing Americans to obtain a different brand of COVID-19 vaccine as a booster than the one they first received.
People familiar with the matter say that when the agency announces the new method, it will not suggest one brand over another, though it may indicate that receiving the same brand for the booster injection is desirable, according to The Times.
The FDA authorized booster doses of the Pfizer-BioNTech vaccine at least six months after the second dosage last month. According to The New York Times, the government is likely to authorize booster doses for the Moderna and Johnson & Johnson vaccinations by Wednesday evening.
The FDA’s anticipated clearance comes following the publication of the first major US research last week, which tested utilizing various boosters of Moderna, Pfizer, and Johnson & Johnson’s COVID-19 injection than the one originally received.
The results demonstrated that the “mix-and-match” approach could be utilized securely. Increasing J&J with Moderna or Pfizer, according to Insider’s Hilary Brueck and Andrew Dunn, may result in a greater immunological reaction initially.
What the study indicates is that being boosted with one of the three vaccines that we assessed, the one from Moderna, the one from Janssen, and the one from Pfizer, resulted in excellent antibody responses in each of the groups.
During a committee meeting this month, Dr. Amanda Cohn, a representative from the Centers for Disease Control and Prevention, remarked that she does not feel there is “any necessity” to have a brand preference for mixing and matching.
From a public health viewpoint, there is a clear need for individuals to receive a different vaccination in some instances. Cohn also noted that people who received the Johnson & Johnson vaccination in a single dosage may benefit from a combination of booster injections.
Many of those patients might not be able to get a second dosage of J&J. Those folks are left behind if there is no authorized wording in the FDA fact sheets or EUA authorization.
According to Dr. Michael Kurilla, an immunologist at the National Institutes of Health, the “mix-and-match” study’s “safety data is fantastic.” At the October 15 meeting, Kurilla prophesied, “I feel we’ll end up in a situation comparable to influenza.” “No one discusses what influenza vaccination you had last year since we don’t have a EUA or clearance for a specific booster for you if you received a specific vaccine.”